Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

a milestone payment from Johnson &

Johnson Pharmaceutical Research and Development, LLC (J&JPRD) triggered

by J&JPRD's selection of a compound targeting the Cathepsin S enzyme as

a development candidate emerging from a collaboration with Sunesis.

-- Lesley A. Stolz, Ph.D., joined Sunesis in November 2007 as Vice

President, Corporate and Business Development.

Financial Highlights

-- Revenue totaled $2.0 million and $9.7 million, respectively, for the

three months and year ended December 31, 2007, compared to $2.0 million

and $13.7 million for the three months and year ended December 31,

2006. The decrease in revenue year-over-year was primarily due to

lower milestone payments from Merck & Co., Inc. in 2007 compared to

2006.

-- Research and development (R&D) expense was $8.3 million for the fourth

quarter of 2007, compared to $8.5 million for the same period in 2006.

R&D expense for the year ended December 31, 2007 totaled $36.1 million,

compared to $35.6 million in 2006. The year-over-year increase in R&D

expense was primarily due to increased clinical trial activity for SNS-

595 and preclinical program costs, partially offset by lower headcount

and lower R&D expense associated with SNS-032 and SNS-314 due to

reduced research activities in these programs.

-- General and administrative (G&A) expense for the fourth quarter of 2007

was $2.8 million, compared to $3.4 million for the fourth quarter of

2006. For the year ended December 31, 2007, G&A expense was $13.6

million, compared to $12.3 million in 2006. The quarter-over-quarter

decrease primarily resulted from lower professional services expense in

2007 compared to 2006. The year-over-year increase in G&A expense was

primarily due to increased non-cash stock-based compensation expense,
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 The largest international ... medicinal plants and therapeutic derivatives thereof has endorsed ... and researchers about the challenges of adulterated herb ... ) The Society for Medicinal ...
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
(Date:1/14/2014)... WESTBOROUGH, Mass. , Jan. 14, 2014  RXi ... on discovering, developing and commercializing innovative therapies addressing ... announced that it received the Notice of Allowance ... on its unique self-delivering RNAi compounds (sd-rxRNA®), for ...
(Date:1/14/2014)... Kinaxis ®, provider of RapidResponse ®, a cloud-based supply ... ( S&OP ) service, is proud to be a gold ... held at the Hilton San Diego Bayfront, January 30 – ... Kaszas , Director of Supply Chain at Amgen, as she ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... DIEGO, Jan. 3, 2012  Amylin Pharmaceuticals, Inc. (Nasdaq: ... Morgan Healthcare Conference in San Francisco on Monday, January 9, ... Daniel M. Bradbury, president and chief executive officer of ... presentation and break-out session will be webcast through the "Investors" ...
... Renowned biochemist Michael A. Marletta, PhD, assumed the post ... January 1, succeeding Richard A. Lerner, MD, who led ... (Photo:  http://photos.prnewswire.com/prnh/20120102/DC28698 ) "I,m excited ... knowledge in the biosciences and applying that knowledge to ...
... BioNeutral Group, Inc. (OTCBB: BONU), a specialty life ... received $400,000 in connection with the Preferred Stock ... ("Vinfluence"), New South Wales, Australia.  Pursuant to the ... initial closing and a second funding of $200,000, ...
Cached Biology Technology:Michael A. Marletta Takes Office as New President of Scripps Research Institute 2BioNeutral Group Receives $400,000 in Equity Financing 2BioNeutral Group Receives $400,000 in Equity Financing 3
(Date:4/23/2014)... who have had a stroke, often suffer motor deficits ... study conducted in Taiwan, that will be published in ... is currently freely available on-line as an unedited early ... one group of stroke victims had their own peripheral ... and a similar group did not, those who received ...
(Date:4/23/2014)... the energy landscape in the U.S., but in ... the energy industry, residents and agricultural interests over ... degraded water quality is a potential risk unless ... in the ACS journal Environmental Science & ... point out that a major criticism of extracting ...
(Date:4/23/2014)... Climate fiction, or simply cli-fi, is a newly coined term ... global warming. New research from University of Copenhagen shows how ... to simulate the potential consequences of climate change and imagine ... than scientific data on changes in the atmosphere; it is ... by the books we read and the films we see. ...
Breaking Biology News(10 mins):Autologous stem cell therapy improves motor function in chronic stroke victims 2How to avoid water wars between 'fracking' industry and residents 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3
... as calcified, inert structures, but researchers at Columbia University ... important novel function of the skeleton. Theyve shown for ... organ that helps control our sugar metabolism and weight ... development of type 2 diabetes. The research, ...
... passed on from mother to child is decided very early ... ovary. In a cell division process that is unique to ... egg before it is fertilised. Using a powerful microscope, researchers ... how the molecular machinery functions that is responsible for chromosome ...
... Haven, Conn. It is not just whats in your genes, ... between species at least in yeast according to a ... Weve known for a while that the protein coding genes of ... author Michael Snyder , the Cullman Professor of Molecular ...
Cached Biology News:Research shows skeleton to be endocrine organ 2A unique arrangement for egg cell division 2Evolution is driven by gene regulation 2
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... was first identified as the cellular homolog of ... and Jun D have been shown to be ... which are involved in dimerization and DNA binding, ... transcriptional activation, diverge. Antigen: ...
IHC Zinc Fixative - , 1000 ml Consult technical datasheet for details....
... (IC) Fixation Buffer, used in conjunction ... 00-8333), can be used to fix ... intracellular staining of cytokines and other ... have been specially formulated for reducing ...
Biology Products: